Pediatric Use: The effectiveness of OFIRMEV for the treatment of
acute pain and fever has not been studied in pediatric patients
less than 2 years of age. The safety and effectiveness of
OFIRMEV in pediatric patients older than 2 years is supported by
evidence from adequate and well controlled studies in adults with
additional safety and pharmacokinetic data for this age group.